{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:38:11Z","timestamp":1787071091407,"version":"build-2736575974"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To preliminarily evaluate the efficacy and safety of pancreatic intra-arterial infusion chemotherapy (PAIC) with nab-paclitaxel in patients with advanced pancreatic carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Fifteen patients with advanced pancreatic carcinoma received monthly, inpatient, 3-h, continuous PAIC of nab-paclitaxel at 180 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , combined with 60 mg oral tegafur gimeracil oteracil potassium capsule for 2 weeks. The therapeutic courses were repeated every 4 weeks. All patients had a preliminary diagnosis based on clinical symptoms, imaging data (computed tomography or magnetic resonance imaging or positron emission tomography\/computed tomography), and tumor markers. The adverse effects, clinical benefit response (CBR), objective response rate (ORR), median progression free survival (mPFS), and median overall survival (mOS) were monitored.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Fifteen patients with advanced pancreatic carcinoma were enrolled in this study, including 10 male and 5 female patients. The mean age at the time of treatment was 66.3 years (53\u201384 years). A total of 49 cycles of PAIC (mean = 3.27 cycles\/patient) were performed. The most common treatment-related toxicities were alopecia, diarrhea, and nausea\/vomiting. No procedure-related complications were observed. The longest overall survival observed was 22 months and the maximum number of treatments for the same patient was six cycles. PAIC contributed a high rate (13\/15 [86.67%]) and fast (10\/15 [66.67%]) easement of pain, with apparent symptom relief within 24 h, especially local pain symptom. The pain anesis rate was 13 (86.67%). CBR was achieved in 13 (86.67%) patients (95%CI [59.54,98.34]). ORR was achieved in four (26.67%) patients (95%CI [7.79,55.10]). Disease Control Rate was achieved in 14 (93.33%) patients. The mPFS was 5.22 months (interquartile range [IQR], 4.27\u20137.85 months). The mOS was 8.97 months (IQR, 5.65\u201313.70 months).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In this study, the dose of the chemotherapeutics and the schedule of the transcatheter pancreatic arterial chemotherapy perfusion were shown to be safe, well-tolerated, and effective for the relief of clinical symptoms and CBR. These advantages can quickly establish the treatment belief and improve patient quality of life. This regimen requires further investigation in patients with advanced pancreatic carcinoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_819_22","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T08:09:18Z","timestamp":1673424558000},"page":"1945-1951","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Pancreatic intra-arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma: A pilot study"],"prefix":"10.4103","volume":"18","author":[{"given":"Nan","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Cardiac Electrophysiology and Arrhythmia, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pikun","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,1,11]]},"reference":[{"key":"R1-20250514","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S2468-1253(19)30347-4","article-title":"The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017","volume":"4","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R2-20250514","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMsr1714643","article-title":"The IARC perspective on colorectal cancer screening","volume":"378","author":"Lauby-Secretan","year":"2018","journal-title":"N Engl J Med"},{"key":"R3-20250514","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"key":"R4-20250514","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"R5-20250514","doi-asserted-by":"crossref","first-page":"613","DOI":"10.4103\/jcrt.JCRT_1663_20","article-title":"Chinese expert consensus of image-guided irreversible electroporation for pancreatic cancer","volume":"17","author":"Wei","year":"2021","journal-title":"J Cancer Res Ther"},{"issue":"Supplement","key":"R6-20250514","doi-asserted-by":"crossref","first-page":"S730","DOI":"10.4103\/0973-1482.188292","article-title":"Evaluation of the use of nab-paclitaxel and gemcitabine in clinical practice","volume":"14","author":"Casanova-Martinez","year":"2018","journal-title":"J Can Res Ther"},{"key":"R7-20250514","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1245\/s10434-010-1384-6","article-title":"Perioperative intra-arterial and systemic chemotherapy for pancreatic cancer","volume":"18","author":"Takamori","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"R8-20250514","doi-asserted-by":"crossref","first-page":"15929.","DOI":"10.1038\/s41598-019-52490-1","article-title":"A study comparing the effects of targeted intra-arterial and systemic chemotherapy in an orthotopic mouse model of pancreatic cancer","volume":"9","author":"Rezaee","year":"2019","journal-title":"Sci Rep"},{"key":"R9-20250514","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000518257","article-title":"The role of hepatic arterial infusion chemotherapy in the treatment of hepatocellular carcinoma: A systematic review and meta-analysis","volume":"66","author":"Li","year":"2021","journal-title":"Chemotherapy"},{"key":"R10-20250514","first-page":"2801","article-title":"Transcatheter arterial infusion for pancreatic cancer: A 10-year National Cancer Center experience in 115 patients and literature review","volume":"44","author":"Qiu","year":"2019","journal-title":"AbdomRadiol (NY)"},{"key":"R11-20250514","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National cancer institute of the United States, National cancer institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 1","key":"R12-20250514","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S0959-8049(96)00324-3","article-title":"Assessing clinical benefit in the treatment of pancreas cancer: Gemcitabine compared to 5-fluorouracil","volume":"33","author":"Burris","year":"1997","journal-title":"Eur J Cancer"},{"key":"R13-20250514","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1007\/s00432-019-03019-6","article-title":"Intra-arterial infusion chemotherapy versus isolated upper abdominal perfusion for advanced pancreatic cancer: A retrospective cohort study on 454 patients","volume":"145","author":"Aigner","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"R14-20250514","doi-asserted-by":"crossref","first-page":"5962","DOI":"10.3748\/wjg.v23.i32.5962","article-title":"Real time endoscopic ultrasound elastography and strain ratio in the diagnosis of solid pancreatic lesions","volume":"23","author":"Okasha","year":"2017","journal-title":"World J Gastroenterol"},{"key":"R15-20250514","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"R16-20250514","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/oxfordjournals.annonc.a010600","article-title":"A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer","volume":"7","author":"Rothenberg","year":"1996","journal-title":"Ann Oncol"},{"key":"R17-20250514","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"key":"R18-20250514","doi-asserted-by":"crossref","first-page":"142.","DOI":"10.3390\/cancers9100142","article-title":"The role of platelet-derived ADP and ATP in promoting pancreatic cancer cell survival and gemcitabine resistance","volume":"9","author":"Elaskalani","year":"2017","journal-title":"Cancers (Basel)"},{"key":"R19-20250514","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4251\/wjgo.v9.i1.37","article-title":"Epithelial-mesenchymal transition as a therapeutic target for overcoming chemoresistance in pancreatic cancer","volume":"9","author":"Elaskalani","year":"2017","journal-title":"World J Gastrointest Oncol"},{"key":"R20-20250514","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jbior.2017.11.007","article-title":"Molecular and cellular mechanisms of chemoresistance in pancreatic cancer","volume":"68","author":"Adamska","year":"2018","journal-title":"Adv Biol Regul"},{"key":"R21-20250514","first-page":"1769","article-title":"Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer","volume":"12","author":"De Luca","year":"2018","journal-title":"Drug Des DevelTher"},{"key":"R22-20250514","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/bjc.2016.185","article-title":"Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer","volume":"115","author":"Chiorean","year":"2016","journal-title":"Br J Cancer"},{"key":"R23-20250514","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.pan.2018.10.004","article-title":"Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study","volume":"19","author":"Rivera","year":"2019","journal-title":"Pancreatology"},{"key":"R24-20250514","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1038\/s41416-020-0846-2","article-title":"Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma","volume":"122","author":"Corrie","year":"2020","journal-title":"Br J Cancer"},{"key":"R25-20250514","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejca.2018.06.001","article-title":"Safety and efficacy of Nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer suffering from cholestatic hyperbilirubinaemia-A retrospective analysis","volume":"100","author":"Pelzer","year":"2018","journal-title":"Eur J Cancer"},{"key":"R26-20250514","doi-asserted-by":"crossref","first-page":"19281.","DOI":"10.1038\/s41598-020-76465-9","article-title":"Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer","volume":"10","author":"Roviello","year":"2020","journal-title":"Sci Rep"},{"key":"R27-20250514","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s00432-020-03442-0","article-title":"Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: A randomized study","volume":"147","author":"Zong","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"R28-20250514","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/jso.2930570212","article-title":"Total abdominal perfusion (TAP) in the treatment of abdominal metastatic melanoma","volume":"57","author":"Klein","year":"1994","journal-title":"J Surg Oncol"},{"key":"R29-20250514","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4103\/jcrt.JCRT_773_18","article-title":"Irreversible electroporation and adjuvant chemoradiotherapy for locally advanced pancreatic carcinoma","volume":"16","author":"Xu","year":"2020","journal-title":"J Can Res Ther"},{"key":"R30-20250514","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pan.2017.11.014","article-title":"Transarterial chemoembolization in pancreatic adenocarcinoma with liver metastases: MR-based tumor response evaluation, apparent diffusion coefficient (ADC) patterns, and survival rates","volume":"18","author":"Vogl","year":"2018","journal-title":"Pancreatology"},{"key":"R31-20250514","first-page":"375","article-title":"Clinical effectiveness of combined interventional therapy as a salvage modality for unresectable pancreatic carcinoma","volume":"18","author":"Das","year":"2019","journal-title":"Oncol Lett"},{"key":"R32-20250514","doi-asserted-by":"crossref","first-page":"652426.","DOI":"10.3389\/fonc.2021.652426","article-title":"Hepatic artery infusion of floxuridine in combination with systemic chemotherapy for pancreatic cancer liver metastasis: A propensity score-matched analysis in two centers","volume":"11","author":"Peng","year":"2021","journal-title":"Front Oncol"},{"key":"R33-20250514","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1158\/1535-7163.MCT-11-0259","article-title":"Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: Toxicity, pharmacokinetics, and activity","volume":"10","author":"Fu","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"R34-20250514","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/cncr.22672","article-title":"Hepatic arterial paclitaxel in breast","volume":"109","author":"Camacho","year":"2007","journal-title":"CA Cancer"},{"key":"R35-20250514","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1002\/1097-0142(20001201)89:11<2195::AID-CNCR7>3.0.CO;2-W","article-title":"Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy","volume":"89","author":"Rivera","year":"2000","journal-title":"Cancer"},{"key":"R36-20250514","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3390\/cancers2031513","article-title":"Neural invasion in pancreatic cancer: The past, present and future","volume":"2","author":"Demir","year":"2010","journal-title":"Cancers (Basel)"},{"key":"R37-20250514","doi-asserted-by":"crossref","first-page":"893.","DOI":"10.3390\/cancers11070893","article-title":"Nerves and pancreatic cancer: New insights into a dangerous relationship","volume":"11","author":"Gasparini","year":"2019","journal-title":"Cancers (Basel)"},{"key":"R38-20250514","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/carcin\/bgt312","article-title":"The neurotrophic factor neurturin contributes toward an aggressive cancer cell phenotype, neuropathic pain and neuronal plasticity in pancreatic cancer","volume":"35","author":"Wang","year":"2014","journal-title":"Carcinogenesis"},{"key":"R39-20250514","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/MPA.0000000000001148","article-title":"Pancreatic cancer-associated depression: A case report and review of the literature","volume":"47","author":"Barnes","year":"2018","journal-title":"Pancreas"},{"key":"R40-20250514","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/cam4.459","article-title":"Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer","volume":"4","author":"Peixoto","year":"2015","journal-title":"Cancer Med"},{"key":"R41-20250514","doi-asserted-by":"crossref","first-page":"6823","DOI":"10.7314\/APJCP.2014.15.16.6823","article-title":"Clinical efficacy of endoscopic pancreatic drainage for pain relief with malignant pancreatic duct obstruction","volume":"15","author":"Gao","year":"2014","journal-title":"Asian Pac J Cancer Prev"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_819_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:41:22Z","timestamp":1787067682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_819_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_819_22","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"2022-04-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}